【长春高新：子公司GenSci128片新药临床试验申请获得美国FDA批准】金十数据5月28日讯，长春高新公告称，公司子公司金赛药业收到美国FDA关于同意GenSci128片开展临床试验的批准。GenSci128片是针对TP53 Y220C突变的选择型重激活剂，用于治疗携带TP53 Y220C突变的局部晚期或转移性实体瘤。该药物已在中国获批开展临床试验。如临床试验申请进展顺利，将有利于公司拓宽业务结构，优化产品结构，并丰富完善战略领域产品线布局、提升公司核心竞争力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.